Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth

Chenjun Bai,1,2 Shanshan Gao,2 Sai Hu,2 Xuemei Liu,1 Hui Li,1 Jie Dong,1 Aixue Huang,1 Lingling Zhu,1 Pingkun Zhou,2 Shaohua Li,1,3 and Ningsheng Shao1

1Institute of Military Cognition and Brain Sciences, Beijing 100850, China; 2Institute of Radiation Medicine, Beijing 100850, China; 3The Fifth Medical Center of PLA General Hospital, Beijing 100039, China

In this study, the CAR-like multivalent aptamer nanoparticles (X-polymers) were assembled with the dimer of murine CD28 RNA aptamer (CD28Apt7), the tetramer of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) RNA aptamer (Del60), and a folic acid labeled ssDNA fragment in a stable nucleic acid three-way junction scaffold (3WJ). Results showed that the X-polymers could recognize both the mCD28 and mCTLA-4 molecules. Confocal imaging and flow cytometry assays showed that the X-polymers could target both T cells and B16 cells in vitro. With the first costimulatory signals provided by the CD3 antibodies, the X-polymers could increase T cell proliferation and reverse the inhibitory effect of interleukin-2 (IL-2) secreting caused by exogenous B7.1 molecules on T cells in vitro. Results of our study also showed that X-polymers could inhibit mouse melanoma B16 cell growth both in vitro and in vivo. Our study demonstrated for the first time that the multivalent aptamer nanoparticle-activated T cells could fulfill the function of CAR-T, which promised a novel approach to developing a multi-functional design of aptamer drugs with potential CAR-like characteristics to enhance the safety of CAR-T cell immunotherapy.

INTRODUCTION
Tumor cells generated by genetic or epigenetic mutations express specific antigens, known as neo-antigens. These cells are usually monitored and eliminated once identified in vivo by the immune system. However, some tumor cells can evade the recognition of T cells, resulting in immune escape or tolerance. Immunotherapy of tumors refers to the restoration of the body's anti-tumor immune response by means of the patient's own immune response or drug assistance so that malignant tumor cells caused by gene mutation can be eliminated and immune surveillance can be performed. A number of immunotherapeutic strategies, including monoclonal antibodies, immune adjuvants, tumor vaccines, and CAR-Ts (chimeric antigen receptor T cells), have been widely used for the treatment of tumors so far.

Despite the varied causes of tumor immune escape, researchers have focused their attention on tumor immune escape caused by inhibited costimulatory molecules in recent years. Most of these costimulatory molecules belong to B7/CD28 immunoglobulin superfamily and tumor necrosis factor superfamily. Also, these molecules were named immune checkpoints as they are positively or negatively involved in the regulation of immunity. Immunotherapy of tumors based on immune checkpoints has developed rapidly in recent years. Monoclonal antibodies targeting CD28, CTLA-4, PD1, and PDL1 have been selling well on the market. More inspiringly, CAR-T, as a new tool based on immune checkpoint-modified T cells, has achieved remarkable results in the immunotherapy of tumors.

CAR-T refers to the use of chimeric antigen receptors to modify T cells so that T cells can play a more targeted and lethal role. The structure of CARs consists of an extracellular binding region, transmembrane region, and intracellular signal transduction region. What is critical about CARs is the extracellular recognition region for identifying tumors and generating activation signals and the intracellular signal transduction region for transducing stimulating proliferation signals to T cells, resulting in T cell proliferation and secreting cytotoxic factors. The most common extracellular recognition antigen is the CD19 molecule, which is used in the treatment of B cell malignant tumors by CAR-T. According to the different intracellular signal transduction regions, the first generation of the CAR system contains only one CD3ζ chain to transmit signals. On the basis of the first generation, the second- and third-generation CAR systems add one or two costimulatory signal units, such as CD28 or 4-1BB, to promote T cell proliferation, secrete costimulatory factors, and prolong the survival time of T cells.

Compared with the aforementioned methods of tumor immunotherapy, CAR-T is flexible and changeable, and its strong adaptability...
to individualized treatment of cancer patients has come to the attention of not only scholars, but also biotechnology and pharmaceutical companies. Over the past two decades, CAR-T-related research has made breakthroughs in animal and clinical experiments and has shown good performance in the treatment of malignant tumors such as lymphoma and B cell leukemia. In August 2017, the first CAR-T drug, named Kymriah, was approved for marketing. Targeting CD19 to treat acute lymphoblastic leukemia (ALL) opened a new era of cell therapy.

The aptamers were first reported by Ellington and Szostak and Tuerek and Gold in 1990. The aptamer is a short single-stranded nucleic acid (20- to 90-nt length) obtained by systematic evolution of ligands by exponential enrichment (SELEX) technology. It is a complex three-dimensional structure formed by interactions between single-stranded oligonucleotide bases and a specific binding of target substances, such as small molecules, proteins, living cells, and pathological sections. The aptamer has low immunogenicity and low molecular weight. When acting on the body as a drug or molecular delivery carrier, it will not produce few allergic reactions. As an alternative of antibody, it is widely used in diagnosis of diseases and drug development. For example, Han and Lee used RNA aptamers to rapidly diagnose Salmonella typhimurium infection. Liu et al. screened out an RNA aptamer binding to bovine thrombin, which could inhibit bovine coagulation activity. NX1838, as an aptamer for clinical treatment, could target vascular endothelial growth factors and has a good therapeutic effect against senile macular disease (ARMD). In recent years, the research of aptamers in the immunotherapy of tumors has also attracted much attention. The earliest aptamers related to immunity are the adaptors of CD4+ T cells. After a long period of research, these adaptors have proved to be able to inhibit virus replication and cytotoxicity. In 2003, Santulli-Marotto et al. demonstrated that the aptamer of CTLA-4 could be used in the immunotherapy of tumors. Since then, many immunotherapy-related aptamers have been reported, and the targets include CD28, OX40, PD1, VCAM1, P-selectin, and interferon (IFN)-gamma, transforming growth factor β (TGF-β), as well as other cytokines.

In this study, we intended to build self-assembled multivalent CAR-like aptamer nanoparticles, which can activate T cells while targeting B16 mouse melanoma tumor cells. The CAR-like multivalent aptamer nanoparticles (X-polymers) were assembled with the dimer of murine CD28 RNA aptamer (CD28Apt7, published by Pastor et al.) and the tetramer of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) RNA aptamer (Del60, published by Santulli-Marotto et al.), as well as a folic acid labeled single stranded DNA (ssDNA) fragment in a stable nucleic acid three-way junction scaffold (3WJ). The aptamer CD28Apt7 was used for supplying the costimulatory signals to activate T cells, and the aptamer Del60 was used for immune checkpoint blockade. The folic-acid-labeled ssDNAs were used for targeting cancer cells. Our results showed that the X-polymers could target both T cells and B16 cells in vitro. With the CD3 antibodies providing the first costimulatory signals, the X-polymers could activate T cells to become CAR-like T, which could inhibit the melanoma growth in vitro. The results also showed that X-polymer nanoparticles could inhibit B16 cell growth in vivo. We demonstrated for the first time that the multivalent aptamer nanoparticle-activated T cells could fulfill the function of CAR-T. Our research can facilitate the development of a multi-functional design of aptamer drugs with potential CAR-like characteristics to improve the safety of CAR-T cell immunotherapy.

RESULTS
Specific Binding of Aptamers to Their Target Proteins
It is well known that T cells are activated through stimulation of the first and second signals before proliferation and differentiation. At the same time, immune checkpoint molecules such as PD1 and CTLA-4 are expressed on the surface of T cells exerting the negative feedback regulation, which will induce the immune escape of tumor cells when combined with ligands expressed on the surface of tumor cells. In order to effectively activate T cells, we used mouse CD28 RNA aptamer (CD28Apt7) as the activation factor and mouse CTLA-4 RNA aptamer (Del60) as the blocking factor of immunosuppressive pathway. We began by verifying the binding of aptamers to their target proteins by electrophoretic mobility shift assay (EMSA) and cold competitive binding assay. The results showed that CD28Apt7 and Del60 could specifically bind to CD28 and CTLA-4, respectively, in a concentration-dependent manner (Figures 1A–1D). According to the literature, the function of the CD28 aptamer in binding to CD28 molecules is in the form of dimer, so we verified the binding of the CD28 dimer to the CD28 protein by EMSA also. Results showed that the dimer of CD28Apt7 could also bind to mCD28 (Figures 1E and 1F). The binding of aptamers to their targets was also confirmed with a dual-channel surface plasmon resonance (Reichert4SPR) (Figure 2).

Self-Assembly of X-polymer Nanoparticles and Verification of Their Binding to Target Proteins
X-polymer nanoparticles were constructed with a modified pRNA-3WJ central skeleton region and external aptamer functional region. The modified 3WJ structure was composed of two RNA sequences and one ssDNA sequence paired by complementary bases (Figure 3A). As shown in Figures 3B and 3C, the X-polymer nanoparticles were composed of one RNA sequence (named the T-p sequence), three ssDNA sequences (named Del60-3WJ, 3WJ-2Del60, and TRS, respectively), and four Del60 aptamers. In the T-P sequence, the CD28Apt7 dimer was inserted between two RNA fragments of the 3WJ structure. The Del60-3WJ sequence was the ssDNA sequence of 3WJ in which the 5’ ends were extended to complement to the folic-acid-modified TRS sequence and the 3’ ends were extended to the sequence complementary overlapping with two Del60 aptamers. 3WJ-2Del60 was a biotin-modified ssDNA sequence partially complementary to the Del60-3WJ sequence and overlapping with another two Del60 aptamers. EMSA results showed that the X-polymer nanoparticles were successfully self-assembled with the strands of Del60, 3WJ-2Del60, Del60-3wj, TRS, and T-p at a molar concentration ratio of...
4:1:1:1 in PBS buffer (Figures 4A and 4B) and could specifically bind to CD28 and CTLA-4 but not TIM3 (Figure 4C).

X-polymer Nanoparticles Specifically Bind to Mouse T Cells and Tumor Cells

T lymphocytes purified from the mouse spleen were recognized by allophycocyanin (APC)-labeled anti-CD3 antibody. The carboxyfluorescein (FAM)-labeled TRS ssDNA strand in X-polymer nanoparticles was used to indicate the binding of X-polymer nanoparticles to targeting cells. Confocal imaging showed that X-polymer nanoparticles could specifically bind to T cells (Figure 5A). The binding of X-polymer nanoparticles to T cells was also confirmed by flow cytometry assay (Figure 5B).

As epithelial-derived tumor cells highly express folate receptors, the folate labeled 5′ end of TRS in X-polymer nanoparticles may specifically bind to tumor cells expressing folate receptors. Our results showed that Cy5-labeled X-polymer nanoparticles could specifically bind to epithelial-derived mouse melanoma B16 cells (the results of folate receptor expression in B16 cells were as follows in Figure S1) and colon cancer MC38 cells rather than human normal hepatocyte L02 cells by confocal imaging (Figures 5C–5E). To find out whether the binding sites of X-polymer nanoparticles were on the surface of living cells, carboxyfluorescein succinimidyl amino ester (CFSE) (green fluorescence) was used to stain the cytoplasm of B16 cells and L02 cells, while Hoechst reagent (blue fluorescence) was used to indicate the nucleus of MC38 cells.

X-polymer Nanoparticles Promote Mouse T Cell Proliferation and Blockade T Cell Immunosuppression In Vitro

The purified mouse T cells were labeled with CFSE and cultured on a 96-well plate with 1640 medium containing 10% fetal bovine serum. CFSE reagent labeling is one of the common methods to detect the proliferation of immune cells. CFSE reagent has no color and fluorescence until the esterase in the cell removes its acetate group and produces a carboxyl fluorescein succinimide ester that

Figure 1. Verification of the Binding of Aptamers to Their Target Proteins

Aptamers were modified with a 3′-terminal biotin modification kit, incubated with the target proteins in EP tube and analyzed by 8% or 10% native PAGE gel. (A and C) The binding of CD28Apt7 to CD28 protein (A) and Del60 to CTLA-4 protein (C). The more protein added, the more obvious the binding band was. BSA or TIM3 were used as the negative control target proteins. (B and D) The cold competitive binding results of the aptamers to CD28 protein (B) and CTLA-4 protein (D), respectively. The biotin unlabeled aptamer was used to compete the biotin labeled aptamer to the same target protein. (E and F) The binding (E) and cold competitive binding (F) of the dimer of CD28Apt7 to CD28 proteins.
can emit bright fluorescence. Once T cells divide, CFSE fluorescence values are evenly distributed in two progeny cells to indicate cell proliferation and are detected by flow cytometry. For T cell proliferation, anti-mouse CD3 antibodies were used to provide the first signal, and X-polymer nanoparticles (with 2-fluorine modification of U and C bases) or anti-CD28 antibodies were used to provide the second signal as a positive control.

The results showed that with the help of CD3 antibody stimulation, the X-polymer nanoparticles could significantly activate T cells and promote CD4+ T cell proliferation in vitro. Compared with the control aptamer (conApt), the percentage of parental T cells significantly decreased after 72 h of stimulation by X-polymer nanoparticles, which was similar to the result of CD28 antibody simulation. Results also showed that X-polymer without T-p sequence had no effect on the proliferation of T cells. There was significant difference between the groups of X-polymer with T-p and X-polymer without T-p for T cell proliferation (p < 0.001). It was proved that the effect of X-polymer on T cell proliferation was mainly induced by a T-p sequence that contained the dimer of CD28Apt7. There was no significant difference in T cell proliferation between the groups of X-polymer without T-p and conApt groups, indicating that the T cell stimulation in these two groups was mainly induced by CD3Anti antibodies (Figures 6A and 6B). However, the proliferation of CD8+ T cells was not obvious, because there was no antigen stimulation in vitro (Figure S2).

IL-2, as one of the important cytokines secreted by T cells, can help promote the growth and differentiation of T cells. The content of IL-2 in the cell supernatant could reflect the effect of the inhibitory pathway blocking. To test the extent to which the X-polymer nanoparticles or Del60 aptamer can inhibit T cell immunosuppressive pathway, IL-2 content in the cell supernatant was measured by ELISA. The results showed that the content of IL-2 in the T cell supernatant increased significantly after anti-CD3 antibodies and anti-CD28 anti-

Figure 2. The Binding of Aptamers to Their Targets Confirmed with SPR
Biotin-modified aptamers (200 nM) bind to streptavidin-labeled chips as solid phase, and target protein (1 μM) served as the mobile phase. The incubation buffer and cleaning buffer used was 20 mM HEPES, 150 mM NaCl, 2 mM CaCl2 (pH 7.4–7.6). (A) The binding of CD28Apt7 (blue), Del60 (green), and NC (red) to CD28 protein. (B) The binding of CD28Apt7 (blue), Del60 (green), and NC (red) to CTLA-4 protein. (C) The binding of CD28Apt7 (blue), Del60 (green), and NC (red) to a negative control protein (TIM3).

X-polymer Nanoparticles Inhibit Mouse Melanoma B16 Cell Growth Both In Vitro and In Vivo
Activated T cells could kill target cells by complicated means, such as by differentiating into cytotoxic T lymphocyte (CTL) cells, secreting perforin, granulase, interferon, and other factors, or activating the Fas pathway. We detected the killing ability of activated T cells by measuring the secretion of IFN-γ and granzyme B. The results showed that the secretion of IFN-γ and granzyme B increased significantly after T cell activation stimulated by X-polymer nanoparticles compared with the control group (Figures 7A and 7B). To test their ability to directly kill tumor cells, X-polymer nanoparticle-activated T cells were co-incubated with melanoma B16 cells in vitro. Flow cytometry assay results showed that the apoptotic rate of B16 cells increased significantly, indicating that X-polymer nanoparticles could activate T cells that had enough cytotoxicity to target tumor cells (Figure 7C). At the same time, X-polymer nanoparticles alone did not cause the apoptosis of B16 cells (Figure S3).

We injected B16 mouse melanoma cells into C57 mice by subcutaneous injection and established a mouse tumor model. After the administration of X-polymer nanoparticles subcutaneously, tumor growth was significantly inhibited. X-polymer nanoparticles had a similar effect to anti-CD28 antibodies combined with anti-CTLA-4 antibodies (Figure 8). The results indicated that X-polymer nanoparticles could inhibit B16 cell growth in vivo.

DISCUSSION
The concept of self-assembled multivalent aptamer nanoparticles with potential CAR-like characteristics has been proposed for the first time in this study. Generally, any aptamers targeting immune checkpoints can be used for assembling multivalent aptamer nanoparticles, but what matters most is the binding activity of the aptamer to its
To select the right aptamers, either the single-stranded DNA or RNA can be used, but assembled multivalent polymers whose components are all RNA molecules can be easily produced by direct transcription *in vitro*. In this paper, the CAR-like X-polymer nanoparticles were assembled with the dimer of CD28Apt7 and the tetramer of Del60, which could blockade the CD28 and CTLA-4, respectively. To prevent the formation of mismatched polymers, a stable intermediate 3WJ sequence was used as the skeleton structure. As far as we know, the safety related to modifying and expanding CAR-T cells poses an obstacle to their clinical application. First, CAR-T therapy is an *in vitro* genetically modified cell therapy that involves taking T cells out of the patient blood, making autologous T cells express CARs through virus transduction and retransferring them back into the body for treatment. The process of preparing CAR-T is difficult due to the vulnerability to contamination. Second, according to many characteristics of host, tumor, and therapeutic agent, CAR-T therapy can induce inflammatory circuit, which can overwhelm the negative-feedback regulation mechanism of homeostasis and lead to cytokine storm. A few patients also had neurotoxic side effects, allergic reactions, and capillary leak syndrome (CLS). Kymriah, a product of CAR-T, was also questioned after it was launched in 2017. Although the side effects of CAR-T do not occur in every patient, these uncontrollable recurrences pose a threat to the life of patients. In addition, in the process of CAR-T treatment, the targeting recognition of cancer by CAR-T is also a key issue. Many immune-escaping cancer cells lack specific antigens, making it impossible to recognize and activate the CAR system accurately. And in the treatment of cancer with known targets, there is also a “miss-target effect” that is detrimental to normal tissues and organs of the body. Given these drawbacks of CAR-T therapy, the tedious and complicated preparation of CAR-T cells can be avoided, and the risk of introducing foreign pollutants when T cells are extracted or retransferred can be reduced if a chemical drug that activates T cells in the patient’s body can be developed.

Although the mechanism of cytokine storm is still controversial, it is likely that the over-activation of T cells or the over-release of cytokines caused by tumor cell death will lead to the inflammatory response of overload. It is the most urgent problem to be prevented or solved for tumor immunotherapy. We believe that on the basis of theory, the possibly mild T-cell-activating effect of CARs like aptamer drugs may reduce the cytokine burst-release syndrome, which needs to be confirmed in the future experiments.

The RNA molecules used in this paper were all modified with 2’-fluorine to prevent RNase degradation. The modified X-polymer nanoparticles may remain stable for a few days *in vivo*, which would provide mild stimulation of T cells. The controllable short time activation of T cells will put the CAR-like aptamer drugs at the advantage of decreasing the risk of the cytokine burst-release syndrome caused by over-activation of immune response. More importantly, an inadvertently triggered cytokine storm can also be brought under control.
by antagonists of aptamers. The simplest antagonists of aptamers are their reverse complementary RNA or ssDNA sequences.\textsuperscript{23,42} The aptamer will change from a single-chain structure to a double-chain structure when meeting with its reverse complementary sequence, losing its spatial folding ability and proper function eventually. This will make X-polymer nanoparticles safely controlled CAR-like drugs in future clinical applications.

There have been some studies on multifunctional aptamers, called bi-specific aptamers. Both the X-polymer nanoparticles and bi-specific aptamers consist of DNA or RNA aptamers. Bi-specific aptamers are generally composed of two aptamers, in which a simple random double-stranded DNA (dsDNA) sequence (or the same base A or T) forms a hinge connection.\textsuperscript{43,44} The X-polymer has the packaging RNA (pRNA)-like skeleton core sequence with strong binding force and stability. X-polymer targeted three molecular, two of which are surface molecules of T cells and one is surface molecule of tumor cells. The function of X-polymer is also different from that of bispecific aptamers. X-polymer combines with T cells and plays the role of killing tumors with the characteristics of T cells. It is similar to CAR-T in form, so we prefer to call it a CAR-like system.

As mentioned above, the X-polymer nanoparticles can be assembled with any costimulatory molecule or immune checkpoint aptamers needed. It is reported that the combination of immuno-checkpoint molecules that promote or inhibit the activation of T cells plays an important role in anti-tumor immunotherapy.\textsuperscript{45,46} Compared with the single signal activation mechanism of CAR system, the X-polymer nanoparticles with the dual stimulation signals for T cells had unique advantages. By increasing the number of immune checkpoint aptamers or by increasing the synergistic effect with costimulatory molecules, as with the third generation of CAR-T,\textsuperscript{47} the lethality to tumors can possibly be increased. In conclusion, we developed self-assembled CAR-like X-polymer nanoparticles that could activate T cells and effectively inhibit the growth of melanoma B16 cells both \textit{in vitro} and \textit{in vivo}. Our results point to a new direction in which to develop a multi-functional design of aptamer drugs with potential CAR-like characteristics to effectively address the safety concerns about CAR-T cell immunotherapy.

**MATERIALS AND METHODS**

**Cell Culture**
The human immortalized normal hepatocyte cell line LO2 and cell line HepG2 were maintained in our lab. The mouse tumor cell lines B16 and MC38 were purchased from Hunan Fenghui Biotechnology. The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) or RPMI 1640 medium (GIBCO, USA) supplemented with 10% fetal bovine serum (GIBCO) and antibiotics (100 μg/mL streptomycin and 100 U/mL penicillin, Sigma) in a humidified incubator containing 5% CO2 at 37°C.

**Preparation of Aptamers**
The aptamer sequences, DNA templates, and primer sequences used in the experiments were as follows:

Aptamers and skeleton sequences were as follows:

| Del60-3wj | 5’-CTCTCTCCCC AAGCACCAGG CCGGCAGCAC TCTCTCCCGG ATCAATCATG GCAACCCAAG TGCACGC TAC TTTGC-3’ |
| 3WJ-2Del60 | 5’-CTCTCTCCCC AAGCACCAGG CCGGCAGCAC TCTCTCCCGG ATCAATCATG GCAACCCAAG TGCACGC TAC TTTGC-3’ |
| T-p | 5’-GGGCACCCAU AAAAGGGAGA GAGGAAGAGG GAUGGGGAUU AGACCAUAGG CUCCCAACCC CCAUAACCCA GAGGUCGAU GUAUCUGAUC |

**In the experiment, we found that the aptamer control group had nonspecific binding with CD28 protein or T cells \textit{in vitro}, but we confirmed that the control aptamers did not provide the second stimulation signal for T cells. We suspected that CD28 may probably be a nucleic acid binding protein, which also needs to be verified in future experiments.**

In conclusion, we developed self-assembled CAR-like X-polymer nanoparticles that could activate T cells and effectively inhibit the growth of melanoma B16 cells both \textit{in vitro} and \textit{in vivo}. Our results point to a new direction in which to develop a multi-functional design of aptamer drugs with potential CAR-like characteristics to effectively address the safety concerns about CAR-T cell immunotherapy.
Figure 5. X-polymer Nanoparticles Specifically Bind to Mouse T Cells and Tumor Cells
X-polymer nanoparticles (green fluorescence) were assembled with the FAM-labeled 3WJ-2Del60 sequence, and T cells were stained with anti-CD3 antibody (red fluorescence) labeled with APC. The co-localization of APC fluorescence and FAM fluorescence was observed under the confocal microscope (A). The binding of X-polymer nanoparticles to T cells was confirmed by flow cytometry as shown in (B). The Cy5-labeled 3WJ-2Del60 sequence was used to assemble X-polymer nanoparticles (red fluorescence). (C–E) The binding of X-polymer nanoparticles to B16 cells marked with CFSE (green fluorescence) (C), MC38 cells marked with Hoechst reagent (blue fluorescence) (D), and LO2 cells marked with CFSE (green fluorescence) (E) was observed under the confocal microscope. The ruler in the picture indicates a length of 20 μm.

CCC CGG GAG AGAGGAAGAG GGAUGGGGAU UAGAC CAUAG GCUCCCAACC CCCAUAACCC AGAGGUCGAU AGUACUGGAU CCCGGGAAAU AUGGGUGCCC ACAUA CUUUG UUGAUCC-3′
DEL60, 5′-GGGAGAGAGG AAGAGGGAUG GGCCGACGUG CCGCA-3′,
TRS, 5′-GCAAAGTAGC GTGCACT-3′,
CD28Ap7, 5′-GGGAGAGAGG AAGAGGGAUG GGGAUUA GAC CAUAGGCUCC CAACCCCAAU AACCCAGAGG UC GAUAUAC UGGAUACC-3′,
CD28Ap7-dimer, 5′-GGGAGAGAGG AAGAGGGAUG GGGAUUA GAC CAUAGGCUCC CAACCCCAAU AACCCAGAGG UC GAUAUAC UGGAUCCC GGGAUGAGAG GAAAGGGAU GGGAUAGA CCAUAGGCUCC

CCACCCCCCA UAAACCAGAG GUCGUAAGUA CUGGA UCCCC CC-3′,
3WJ1, 5′-UUGCCAUGUG UAUUGGG-3′,
3WJ2, 5′-CCACCAACAU UUGUAUACCC-3′,
3WJ3, 5′-GGATCAATCA TGGCAA-3′.

Double-stranded DNA templates and primers were as follows:

**T-p dsDNA template**, 5′-GAGTCTAATA CGACTCAGTA TAGGGTTGCC ATGTTGATAT GGGCGCCCCAT AAAAGG GAGA GAGGAAGAGG GATGGGGATT AGACCATAGG CTGCCAACC CCATAACCJA GAGGGTGAATA GTACTG GATC CCCCGGGGAG AGAGGAAAG GGAAGGGAAT TA GACCATTAG GCTCACCACC CCATAACCJA AGAGGTCGAT
AGTACTGGAT CCCGGGAAAT ATGGGTGCCC ACATA
CTTTG TTGATCC-3

CD28Ap7-dimer dsDNA template, 5'-GAGTCTAATA CGACTCACTA TAGGGAGAGA GGAAGAGGGA TGGGGATTAGACCATAGGCT CCCAACCCCC ATAACCCAGA GGTCGATAG TACTGGATCCC CCCCGGAGAG AGGAAGAGGG ATGGGGATTA GACCATAGGC TCCCAACCCC CATAACCAG AGGTCGATAG TACTGGATCC CCCCGGAC-3',

XT7 F primer, 5'-GAGTCTAATA CGACTCACTA TAGGG-3',
T-p R primer, 5'-GGATCAACAA AGTATGTGGG C-3',
CD28Ap7 R primer, 5'-GGGGGGATCC AGTACTATC-3'.

Del60, 3WJ1 and, 3WJ2 were synthesized and modified with 2'-fluorine modification of U and C bases by Guangzhou RiboBio. Del60-3wJ, 3WJ2-DEl60, 3WJ3, and primers were synthesized by Sangon Biotech. TRS was synthesized and modified with 5'-folic acid by TAKARA. dsDNA templates were synthesized by TSINGKE Biotechnological Technology. Fluorescence modification of all sequences was by Sangon Biotech. dsDNA templates of CD28Ap7 and CD28Ap7 dimer aptamers were obtained from PCR using XT7 F and CD28Ap7 R primers and purified after gel cutting. RNA aptamers were obtained from their dsDNA templates by a TranscriptAid T7 high-yield transcription kit (Thermo Scientific, K0441) in vitro. 2'-fluorine-modified aptamers for in vitro and in vivo experiments were obtained from their dsDNA templates by a DuraScribe T7 transcription kit (Lucigen, DS010925). The negative control RNA used for EMSA experiments was 3WJ1 (negative control, NC). The negative control fragments for in vitro and in vivo tumor cell experiments were assembled by 3WJ1, 3WJ2, and 3WJ3 at a ratio of 1:1:1 in vitro (conApt).

EMSA

The EMSA experiment was conducted using a chemiluminescent nucleic acid detection module kit (Thermo Scientific Pierce, 89880). The Pierce RNA 3' end biotinylation kit (Thermo, 20160) was used in the 3' end biotin modification of the aptamer. Aptamer denaturation was as follows: RNA aptamers were placed at 85°C for 10 min (dsDNA fragment at 95°C, 10 min) and cooled on ice for 10 min. Target recombinant proteins (mouse CD28, Abcam, ab207143; mouse CTLA-4, Sino Biological, 50503-M08H; mouse PD1, Sino Biological, 50124-M08H;
mouse TIM3, Sino Biological, 51152-M08H; mouse TIGIT, Sino Biological, 50939-M08H) and aptamers were incubated in buffer (20 mM HEPES, 150 mM NaCl, 2 mM CaCl2 [pH 7.4–7.6]) at 37°C for 30–60 min before being applied in native polyacrylamide gel electrophoresis. After being transferred to nylon membrane (GE Healthcare, RPN303B), the shift bands were UV cross-linked (1200 J energy, 254 nm wavelength) for 2 min and imaged using enhanced chemiluminescence (ECL) reagents with Clinx ChemiScope 3400 mini.

### Binding Analysis by SPR

The binding of the aptamers to their target proteins was analyzed by using Reichert4SPR. Biotin-modified aptamers (200 nM) bind to streptavidin-labeled chips as the solid phase, and target protein (1 µM) was used as the mobile phase. The incubation buffer and cleaning buffer used was 20 mM HEPES, 150 mM NaCl, 2 mM CaCl2 (pH 7.4–7.6).

### Self-Assembly of X-polymer Nanoparticles

The X-polymer nanoparticles were assembled in two eppendorf (EP) tubes according to the following system, and the total volume of each tube was 20 µL. EP tube A contained the strands of Del60, 3wj-2Del60, and Del60-3wj. EP tube B contained the strands of T-p and TRS. After the treatment of EP tube A at 95°C 10 min, 4°C 10 min, 22°C 20 min, 47°C 20 min, and 73°C 20 min, the treatment of EP tube B at 85°C 10 min and 4°C 10 min, tube A and B were mixed and incubated at 37°C for 1 h. The strands of Del60, 3wj-2Del60, Del60-3wj, TRS, and T-p were mixed at a molar concentration ratio of 4:1:1:1 in PBS buffer. The assembled X-polymer nanoparticles were stored at –70°C.

### T Cell Proliferation Assay

Spleen tissues of 6- to 8-week-old BALB/c mice (Beijing Vital River Laboratory Animal Technology) were obtained and ground, filtered on a 200 mesh cell sieve, and centrifuged with a horizontal rotor at 650 × g for 30 min by adding Lymphocyte separation medium (Da-kewe Biotech, 7211011). The lymphocyte layer was purified with a nylon hair column (Polyscience, 21759-1) or a mouse CD4/CD8+ T cell isolation kit (Biolegend, 480005/480007) and added to 1640 medium for subsequent experiments. T cells were then stained with CFDA-SE dyes (Invitrogen, C34554). T cells (1.6*10^6/mL) were cultured in 1640 complete medium in a 96-well plate and then incubated with 0.025 µg/well of anti-CD3 antibodies (Biolegend, 100313), 0.5 µg/well of anti-CD28 antibodies (Biolegend, 102111), or 100 pmol/well of aptamers for 72 h. The T cells were detected by flow cytometry. In order to differentiate CD4+ and CD8+ T cells, anti-CD4 antibodies (P-phycoerythrin (PE)-anti-CD4 antibody, Biolegend, 100407) and anti-CD8 antibodies (APC-anti-CD8 antibody, Biolegend, 100711) were stained and analyzed by flow cytometry.

### ELISA

IFN-γ and granzyme B were quantified by ELISA using a mouse IFN-γ ELISA kit (GenStar, C707-02) and a mouse granzyme B ELISA kit (GenStar, C728-02), while IL-2 was quantified by mouse IL-2 ELISA kit (GenStar, C739-02) according to the manufacturer’s instructions.

### Analysis of Blocking T Cell Inhibitory Pathway

T cells were diluted to 1.6*10^6/mL and seeded in a 96-well plate with 200 µL/well. After stimulating the T cell proliferation with anti-CD3 antibodies (0.025 µg/well) and anti-CD28 antibodies (0.5 µg/well),
B7.1 protein (R&D systems, 740-B1-100; 400 ng/well) was added to inhibit T cell proliferation before aptamers (200 pmol/well) or anti-CTLA-4 antibodies (Biolegend, 106204; 1 μg/well) were added separately. Cells were cultured for 72 h. The content of IL-2 in the supernatant of cell culture was detected by ELISA.

Flow Cytometry Assay
T cells (1.2×10^4) were incubated with X-polymer nanoparticles (200 pmol) assembled with fluorescein isothiocyanate (FITC)-labeled TRS sequence or FITC-labeled control adaptor in PBS buffer for 30 min, then washed twice with PBS and detected by flow cytometry. APC-antiCD3 antibody (0.5 μg) was used to label T cells.

Cell Immunofluorescence Assay
For immunofluorescence assay, 2×10^4 cells were seeded in a 15-mm diameter cell dish and cultured in full media for 12 h. The X-polymer nanoparticles assembled by Cy5-labeled 3WJ-2 Del60 sequence were added to the cells and imaged by confocal. CFDA-SE dye or Hoechst reagent (Beyotime, C1029) was used to stain cell cytoplasm and nuclei, respectively.

Apoptosis Assay of X-polymer Nanoparticles to Mouse Melanoma B16 Cells In Vitro
B16 cells (4×10^4/4 well) stained with CFSE were seeded in a 96-well plate and cultured in full medium for 12 h. After the culture media was removed, T cells (2×10^55/well) and aptamers or antibodies were added. After another 48 h of co-culture, the culture media was removed, while cells were trypsinized and resuspended in PBS buffer. The apoptosis rate was analyzed by flow cytometry with Annexin V-PE (Beyotime, C1065).

Animal Experiment
To detect the activity of X-polymer nanoparticles in vivo, C57BL/6J mice (4 weeks old, obtained from Beijing Vital River Laboratory Animal Technology) were injected with 4×10^6 B16 cells into left subscapular tissues. The aptamers (400 pmol per mouse) or anti-CD28 antibodies plus anti-CTLA-4 antibodies (anti-CD28 antibody, 4 μg per mouse; anti-CTLA-4 antibody, 8 μg per mouse) were simultaneously administrated into subcutaneous tissues next to the injection site. The total number of times of injections was four. The first and second injections were given every 3 days, while the other injections were given every 2 days, and the dose of the first injection was 400 pmol per mouse. On the ninth day, most of the mice grew tumors. There were obvious protrusions under the left scapula of the mice. On the 13th day, when the growth of tumors in the control group was close to 1 cm³, the tumors were removed for measurement. Tumor volumes were calculated as 0.5×a (length)×b (width)^2.

Statistical Analysis
Data was analyzed by using GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). For ELISA assay and T cell proliferation assay, the standard deviation (±SD) was obtained for the three parallel groups of data, and the experiments were repeated three times. We used one-way ANOVA statistics to compare the difference between more than two groups. p < 0.05 was considered statistically significant.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.omto.2020.03.002.
AUTHOR CONTRIBUTIONS
N.S., S.L., and P.Z. designed the study. N.S. and C.B. wrote the manuscript. C.B., S.G., and S.H. contributed to carrying out the experiments. X.L., H.L., J.D., A.H., and L.Z. provided technical support.

CONFLICTS OF INTEREST
The authors declare no competing interests.

ACKNOWLEDGMENTS
We thank Professor Xiansheng Lu for his help in linguistic revision. This work was supported by the Key R&D of the Ministry of Science and Technology of China (2017YFC1200900 to N.S. and 2016YFC1309604 to S.L.).

REFERENCES
1. Sharma, P., Wagner, K., Wolchok, J.D., and Allison, J.P. (2011). Novel cancer immuno-therapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11, 805–812.
2. Chen, L., and Flies, D.B. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242.
3. Sharma, P., and Allison, J.P. (2015). Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214.
4. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Marc, L., Raffeld, M., Nathan, D.A., Lanier, L.J., et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102.
5. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., and June, C.H. (2011). Chimeric anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 8, 336–348.
6. Weijtens, M.E., Willemsen, R.A., Valerio, D., Stam, K., and Bolhuis, R.L. (1996). Conjugation to polyethylene glycol polymer promotes aptamer bio-distribution to healthy and inflamed tissues. Oligonucleotides 6, 658–667.
7. Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M., Varella-Rehena, A., Haines, K.M., Heijtjan, D.F., Albeda, S.M., et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106, 3360–3365.
8. Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M., and Brentjens, R.J. (2012). Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141.
9. June, C.H., Riddell, S.R., and Schumacher, T.N. (2015). Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 7, 280ps7.
10. Kochenderfer, J.N., and Rosenberg, S.A. (2013). Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10, 267–276.
11. Mazzarella, L. (2014). Tales from the Jazz ASE: highlights from the 2013 American Society of Haematology meeting. Eancermedicalsceince 8, 390.
12. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518.
13. Ellington, A.D., and Szostak, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818–822.
14. Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505–510.
15. Groher, F., and Suess, B. (2016). In vitro selection of antibiotic-binding aptamers. Methods 106, 42–50.
16. Bock, L.C., Griffin, L.C., Latham, J.A., Vermaas, E.H., and Toole, J.J. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564–566.
17. Lou, X., Qian, J., Xiao, Y., Viel, L., Gerdon, A.E., Lagalley, E.T., Atzberger, P., Tarasov, T.M., Heeger, A.J., and Soh, H.T. (2009). Micromagnetic selection of aptamers in microfluidic channels. Proc. Natl. Acad. Sci. USA 106, 2989–2994.
18. Shangguan, D., Li, Y., Tang, Z., Cao, Z.C., Chen, H.W., Malikartachy, P., Sefah, K., Yang, C.J., and Tan, W. (2006). Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 103, 11838–11843.
19. Wang, C., Zhang, M., Yang, G., Zhang, D., Ding, H., Wang, H., Fan, M., Shen, B., and Shao, N. (2003). Single-stranded DNA aptamers that bind differentiated but not parental cell lines: selective survival evolution of ligands by exponential enrichment. J. Biotechnol. 102, 15–22.
20. Li, S., Xu, H., Ding, H., Huang, Y., Cao, X., Yang, G., Li, J., Xie, Z., Meng, Y., Li, X., et al. (2009). Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J. Pathol. 218, 327–336.
21. Röthlisberger, P., and Hollenstein, M. (2018). Aptamer chemistry. Adv. Drug Deliv. Rev. 134, 3–21.
22. Han, S.R., and Lee, S.W. (2013). In vitro selection of RNA aptamer specific to Salmonella typhimurium. J. Microbiol. Biotechnol. 23, 879–884.
23. Liu, X., Cao, G., Ding, H., Zhang, D., Yang, G., Liu, N., Fan, M., Shen, B., and Shao, N. (2004). Screening of functional antibodies of RNA aptamers against bovine thrombin. FEBS Lett. 562, 125–128.
24. Kaiser, P.K. (2006). Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am. J. Ophthalmol. 142, 660–668.
25. Kraus, E., James, W., and Barclay, A.N. (1998). Cutting edge: novel RNA ligands able to bind CD4+ T lymphocyte function. J. Immunol. 160, 5209–5212.
26. Wheeler, L.A., Vрабенак, V., Trifonova, R., Brehm, M.A., Gilboa-Geffen, A., Tannos, S., Greiner, D.L., Luster, A.D., Tager, A.M., and Lieberman, J. (2013). Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol. Ther. 21, 1378–1389.
27. Santulli-Marotto, N., Sair, S.K., Ruscioni, B., Sullivan, E., and Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 63, 7483–7489.
28. Pastor, F., Soldevilla, M.M., Villanueva, H., Kolonias, D., Inoges, S., de Cerio, A.L., Kandzia, R., Klimykuk, V., Gleba, Y., Gilboa, E., and Bendandi, M. (2013). CD28 aptamers as powerful immune response modulators. Mol. Ther. Nucleic Acids 2, e98.
29. Dollins, C.M., Nair, S., Boczkowski, D., Lee, J., Lazzey, J.M., Gilboa, E., and Sullivan, B.A. (2008). Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol. 15, 675–682.
30. Prodeus, A., Abdul-Wahid, A., Fischer, N.W., Huang, E.H., Cydzik, M., and Gariépy, T.M., Heeger, A.J., and Soh, H.T. (2009). Micromagnetic selection of aptamers in microwells. J. Am. Chem. Soc. 131, 13784–13793.
31. Shangguan, D., Li, Y., Tang, Z., Cao, Z.C., Chen, H.W., Mallikaratchy, P., Sefah, K., Yang, C.J., and Tan, W. (2006). Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 103, 11838–11843.
32. Prodeus, A., Abdul-Wahid, A., Fischer, N.W., Huang, E.H., Cydzik, M., and Gariépy, T.M., Heeger, A.J., and Soh, H.T. (2009). Micromagnetic selection of aptamers in microwells. J. Am. Chem. Soc. 131, 13784–13793.
38. Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., and Sadelain, M. (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666–668.

39. Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Vermeiren, M.R., Stefanska, H.E., Myers, G.D., et al. (2018). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439–448.

40. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., and Rosenberg, S.A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851.

41. Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H.J., Schlöfer, H.A., Schaak, M., Kochanek, M., Boll, B., and von Bergwelt-Baldon, M.S. (2018). Cytokine release syndrome. J. Immunother. Cancer 6, 56.

42. Rasconi, C.P., Scardino, E., Layzer, J., Pitoc, G.A., Ortel, T.L., Monroe, D., and Sullenger, B.A. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90–94.

43. Pastor, F., Kolonias, D., McNamara, J.O., 2nd, and Gilboa, E. (2011). Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol. Ther. 19, 1878–1886.

44. Boltz, A., Piater, B., Toleikis, L., Gaenther, R., Kolmar, H., and Hock, B. (2011). Bi-specific aptamers mediating tumor cell lysis. J. Biol. Chem. 286, 21896–21905.

45. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. (2016). Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421.

46. Kamphorst, A.O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D.L., Konieczny, B.T., Daugherty, C.Z., Koenig, L., Yu, K., et al. (2017). Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423–1427.

47. Gross, G., and Eshhar, Z. (2016). Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting On-Tumor Antigenic Xers for Safe CAR T Cell Therapy. Annu. Rev. Pharmacol. Toxicol. 56, 59–83.

48. Mercier, M.C., Dontenwill, M., and Choulier, L. (2017). Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers. Cancers (Basel) 9, E69.